The bank downgraded the Danish pharmaceutical giant to neutral from buy and decreased its price target.
Get this delivered to your inbox, and more info about our products and services.
Novo Nordisk is losing market share despite its having a "comprehensive portfolio" compared to peers, the firm said.
The Wegovy obesity drug maker on Wednesday announced plans to trim 11.5% of its workforce.
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S.…
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise prereleased its 2026…
Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance.
TD Cowen still sees shares of Novo Nordisk adding 6% from here.
Drugmaker Novo Nordisk slashes Wegovy sales forecasts, blaming compounding
